Search research articles
Contact Us
Filters
Showing results (161-170 of 216) with videos related to
Page
of 22
Sort By:
Nature Communications
|
February 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial
Sangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Cancer Discovery
|
November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
The Lancet. Oncology
|
February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
Van K Morris, Mohamed E Salem, Halla Nimeiri, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2023
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Nan Deng, Laura Reyes-Uribe, Johannes F Fahrmann, et al.
Cancer
|
December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L McArthur, Adi Diab, David B Page, et al.
Nature Communications
|
May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
Padmanee Sharma, Michael Krainer, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer
Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Nature Medicine
|
November 28, 2018
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang, Diana H Wiesnoski, Beth A Helmink, et al.
Page
of 22
Search research articles
Search
Showing results (161-170 of 216) with videos related to
Sort By:
Page
of 22
Nature Communications
|
February 21, 2025
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial
Sangeeta Goswami, Jianjun Gao, Sreyashi Basu, et al.
Cancer Discovery
|
November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
The Lancet. Oncology
|
February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study
Van K Morris, Mohamed E Salem, Halla Nimeiri, et al.
The New England Journal of Medicine
|
September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J Motzer, Bernard Escudier, David F McDermott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 19, 2023
Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Nan Deng, Laura Reyes-Uribe, Johannes F Fahrmann, et al.
Cancer
|
December 1, 2018
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 28, 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Heather L McArthur, Adi Diab, David B Page, et al.
Nature Communications
|
May 7, 2026
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial
Padmanee Sharma, Michael Krainer, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 29, 2024
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer
Ana M Aparicio, Rebecca S S Tidwell, Shalini S Yadav, et al.
Nature Medicine
|
November 28, 2018
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang, Diana H Wiesnoski, Beth A Helmink, et al.
Page
of 22